0.850
0.00 (0.00%)
Penutupan Terdahulu | 0.850 |
Buka | 0.850 |
Jumlah Dagangan | 1,258 |
Purata Dagangan (3B) | 11,352 |
Modal Pasaran | 41,488,160 |
Harga / Pendapatan (P/E TTM) | 21.25 |
Harga / Jualan (P/S) | 3.21 |
Harga / Buku (P/B) | 27.96 |
Julat 52 Minggu | |
Tarikh Pendapatan | 20 Feb 2025 - 24 Feb 2025 |
Hasil Dividen (DY TTM) | 2.41% |
Margin Keuntungan | 14.59% |
Margin Operasi (TTM) | 18.04% |
EPS Cair (TTM) | 0.040 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 0.00% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | 36.20% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 168.74% |
Nisbah Semasa (MRQ) | 1.94 |
Aliran Tunai Operasi (OCF TTM) | 2.74 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.13 M |
Pulangan Atas Aset (ROA TTM) | 6.06% |
Pulangan Atas Ekuiti (ROE TTM) | 86.98% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Diagnostics & Research (AU) | Bercampur | Bercampur |
Diagnostics & Research (Global) | Bercampur | Bercampur | |
Stok | CRYOSITE FPO [CTE] | - | - |
AISkor Stockmoo
Konsensus Penganalisis | 0.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 2.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | -0.5 |
Purata | 0.38 |
Cryosite Ltd is engaged in the provision of supply chain logistics, and management of pharmaceutical products used in clinical trials. The company's operating segment includes Cord Blood and Tissue Storage and Clinical Trials and Biological Services Logistics. It generates maximum revenue from the Clinical Trials and Biological Services Logistics segment. The clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labeling, status management, secondary packaging, scheduled drug distribution, destruction, returns, and biological services. |
|
Sektor | Healthcare |
Industri | Diagnostics & Research |
Gaya Pelaburan | Small Core |
% Dimiliki oleh Orang Dalam | 72.29% |
% Dimiliki oleh Institusi | 1.56% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |